Actyon NMDA receptor zinc-binding site modulator

Actyon Discovery is developing a small molecule program that targets the zinc-binding site of the N-methyl-D-aspartate (NMDA) receptor. This approach utilizes the company's proprietary 'metallo-allostery' platform, which identifies small molecules capable of interacting with metal-binding sites on proteins to modulate their function. By targeting the high-affinity zinc-binding site on the NMDA receptor, these compounds aim to fine-tune glutamatergic neurotransmission. The program is primarily focused on treating neurologic and psychiatric disorders characterized by NMDA receptor dysfunction, such as depression, schizophrenia, and cognitive impairment, with the goal of achieving better subtype selectivity and safety compared to traditional NMDA modulators.

Other names

Zinc-modulated NMDA receptor modulatorNMDA receptor zinc-binding site small molecule